FDA charged the Fresenius Medical Care Ogden complaint-trend failure under 21 CFR 211.192, not the complaint-file section at 211.198, so a supplier qualification packet that screens only for 211.198 citations will miss it. Only written, per-lot complaints create the record FDA reads at inspection.
FDA issued Warning Letter #730319 on August 25, 2026 to Fresenius Medical Care AG & Co. KGaA, covering the company's Ogden, Utah facility, FEI 1713747, after an inspection conducted March 2 through 6, 2026. The letter documents a complaint trend the firm logged, investigated, closed at its lowest severity level, and did not act on for eight months. It is the clearest recent illustration of how cGMP complaint handling requirements are actually enforced, and the enforcement does not land where most supplier qualification packets look for it.2
That distinction has a direct consequence for wholesale purchasing. A complaint phoned into a customer service line and settled with a replacement shipment leaves no trace in the file an investigator reads. A written complaint filed against a specific lot number becomes part of the documentary record — the same record that let FDA reconstruct, item by item, what Ogden knew in August 2025 and what it did not do until April 2026.2,10
What the Ogden Letter Actually Cites, and What It Doesn't
The complaint-trend failure at Ogden is charged under 21 CFR 211.192 — the requirement to thoroughly investigate unexplained discrepancies and failures of a batch to meet specifications. It is not charged under 21 CFR 211.198, the complaint-file section. FDA's objection was not that the firm lacked a complaint procedure. The complaints were received, counted, and grouped into a trend. The objection was that the resulting investigation was not thorough and did not drive the action the evidence supported.2
21 CFR 211.198 covers different ground: written procedures for handling all written and oral drug product complaints, and a complaint file maintained at the manufacturing site or another facility readily accessible to the firm. A manufacturer can satisfy that section completely — procedure on file, complaints logged, quality unit signatures in place — and still be cited under 211.192 for what the log did not trigger.10
A keyword search against Ogden's public compliance record for "211.198" returns nothing. The failure mode is there in full, filed under a different regulation. Any qualification checklist built around a single citation string will clear a site that FDA has already documented sitting on a defect trend.2,10
Thirty-Five Complaints, 156 Bags, Eight Months to Recall
The letter lays out a timeline that is unusually legible for a warning letter, because the firm's own records supplied it. The trend was internally recognized before FDA arrived; the inspection did not discover the defect, it discovered the response.2
| Date | Documented event |
|---|---|
| August 2025 | Firm initiates an investigation into a complaint trend of leaking bags of Delflex Peritoneal Dialysis Solution |
| Through the investigation | 35 complaints received, covering approximately 156 bags drawn from multiple batches |
| Investigation conclusion | Leaks attributed to printing-caused holes; lowest severity level assigned |
| After August 2025 investigation | No recall initiated |
| March 2–6, 2026 | FDA inspection of the Ogden, Utah facility, FEI 1713747 |
| April 2026 | Recall of affected product conducted, following the inspection |
| August 25, 2026 | Warning Letter #730319 issued; written response required within 15 working days |
Eight months separate an internal investigation that already had 35 complaints in hand from the recall. The recall followed the inspection rather than the trend. That sequence is the number a purchasing team should carry into a supplier review: not whether a firm has ever recalled product, but how much of its own complaint evidence accumulated before it did.2
The same letter carries a second citation, under 21 CFR 211.100(a), for inadequate written production and process control procedures — specifically an insufficiently qualified visual inspection program for particulates. Particulate detection capability and complaint-trend escalation are separate systems on paper and a single failure in practice: an inspection program that cannot reliably find the defect produces a complaint file that arrives late and reads as noise.2
Why a Phone Call Never Becomes Part of the Complaint File
21 CFR 211.198 requires written procedures covering all written and oral complaints, so an oral report is in scope by regulation. In practice, the record that survives to an inspection is the one that carries a lot number, a date of receipt, a described defect, and a disposition. A call routed to a distribution contact and closed with a credit memo generates a shipping document, not a complaint record.10
The Ogden file worked because 35 discrete complaints were traceable to approximately 156 bags across multiple batches. That batch-level granularity is what turned scattered reports into a trend a regulator could count. Had the same defects been absorbed as replacement shipments without lot attribution, there would have been no trend on file to fail to investigate.2
The purchasing consequence is procedural. A wholesale buyer's leverage over a fill-finish or contract manufacturing partner depends on complaints existing as documents the partner's quality unit must close, with a written closure the buyer can request later. Complaints handled by phone are invisible at renegotiation, invisible during a recall reconstruction, and invisible to the next FDA investigator who walks the complaint file.2,10
211.198 Versus 211.192: Two Different Failures, Two Different Letters
That 211.198 is enforced independently, and against a different failure, is visible in FDA's own letter inventory. A November 5, 2024 warning letter to Colgate-Palmolive/Tom's of Maine cited a failure to establish adequate written procedures for complaint handling and quality-unit review under 21 CFR 211.198(a). That is a firm without an adequate procedure. Ogden had a procedure and used it.10
| Screening question | 211.198 failure | 211.192 failure |
|---|---|---|
| What is missing | Written complaint procedure, quality-unit review, or an accessible complaint file | A thorough investigation of a discrepancy the complaint file already surfaced |
| Illustrative letter | Colgate-Palmolive/Tom's of Maine, November 5, 2024 | Fresenius Medical Care, Ogden, August 25, 2026 |
| What a document request reveals | The SOP itself and evidence that it is followed | Closed investigation records, severity assignments, and recall decisions |
| Why a packet misses it | Rarely — the absence is visible on the SOP index | Routinely — the SOP exists and passes review on its face |
A qualification packet has to test both. Requesting the complaint-handling SOP answers the 211.198 question and nothing else. Requesting closed investigation records tied to named complaint trends answers the 211.192 question, and it is the one that produced an eight-month gap at Ogden.2,10
What Ogden's Risk Management Matrix Discrepancy Means for a Buyer's Own Severity Coding
FDA found that the firm's investigation assigned the lowest severity level to the leaking-bag defect even though the firm's own Risk Management Matrix indicated a higher-severity potential harm. The tool and the output disagreed, and the disagreement was not reconciled in the record.2
That is a specific, checkable defect, and it is checkable from outside the firm. A supplier's complaint-trending summary is a set of severity codes. Those codes are only meaningful against the matrix that generated them. Received on its own, a trending summary showing all low-severity dispositions is uninterpretable — it may reflect a clean quarter or a miscalibrated scale.2
So the request has to be paired: the trending summary and the risk classification matrix that governs it, for the same period. Where a summary shows a defect category recurring across multiple batches at the lowest severity, the matrix will show whether that coding is defensible. At Ogden, it was not, and the printing-caused-holes attribution closed the investigation anyway.2
Assembling a Dual-Qualification Packet Before Next Quarter's Volumes Are Committed
Everything above converts into document requests that can go out with the next round of supplier questionnaires. None of it requires a site visit, and all of it is material a compliant quality unit already maintains.2
- The written complaint-handling procedure, with evidence of quality-unit review, addressing the 211.198 requirement for both written and oral complaints.
- Complaint-file trending summaries for the trailing 24 months, at batch or lot granularity rather than product-family totals.
- The risk classification or severity matrix used to code those complaints, so the summary can be read against the scale that produced it.
- Closed investigation records for any complaint trend crossing the firm's own escalation threshold, including the recall decision and its written rationale.
- Visual inspection program qualification records where particulate detection is part of release, which is where the Ogden letter's 211.100(a) citation sits.
- Warning-letter and Form 483 search results confirmed against the FEI number on the site's own registration for the plant under contract, run separately for each entity named in FDA's letter inventory that shares a corporate brand with it.2,10
The last item carries the most weight for anyone screening a Fresenius entity, and the reason is name collision. FDA's public warning letter inventory holds separate letters to Fresenius Kabi AG dated September 14, 2023 and January 4, 2024, and to Fresenius Kabi Oncology sites dated December 4 and December 17, 2017 — all distinct from Warning Letter #730319 to Fresenius Medical Care's Ogden plant. Matching those four letters against FEI 1713747 rather than the shared Fresenius name rules three of them out immediately and confirms the fourth is the only one touching the Ogden plant.3,4,5,8,2
The GDUFA III Footnote and What It Signals About the Ogden Plant's Timeline
The letter requires a written response within 15 working days describing corrective actions completed or planned, with a schedule where the work cannot be finished in that window. Responses go to Francis Godwin, Director of the Office of Manufacturing Quality in CDER's Office of Compliance, attention Russell Riley. Those are the fixed dates a supply planner can anchor to.2
The more useful signal is a footnote. Under GDUFA III program enhancements, the facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary FDA feedback on its corrective action plans, as stated in the letter itself.2
For a buyer holding volume commitments against a site under a warning letter, eligibility for that meeting is worth asking about directly, and so is whether it has been requested. That is documented correspondence a supplier's quality unit can produce on request, not a signal to infer from the calendar.2